Table 2.
Distribution of psychiatric drugs use in the subset of prostate cancer survivors treated with such medications during follow-up (n = 5931 men)
| N | % | N** | %** | |
|---|---|---|---|---|
| Unit of observation = prescription | Unit of observation = subject | |||
| Anti-anxiety drugs* | 5,999 | 6.6 | 1,046 | 17.6 |
| Antidepressants | ||||
| Monoamine oxidase inhibitors | 360 | 0.4 | 32 | 0.5 |
| Norepinephrine dopamine reuptake inhibitor/Norepinephrine reuptake inhibitor | 8,551 | 9.3 | 962 | 16.2 |
| Serotonin antagonist and reuptake inhibitors | 89 | 0.1 | 14 | 0.2 |
| Serotonin modulator and stimulator | 144 | 0.2 | 8 | 0.1 |
| Serotonin and norepinephrine reuptake inhibitors | 6,704 | 7.3 | 834 | 14.1 |
| Selective serotonin reuptake inhibitors | 41,652 | 45.5 | 3,623 | 61.1 |
| Tricyclic antidepressants | 20,112 | 22.0 | 2,679 | 45.2 |
| Tetracyclic antidepressants | 4,835 | 5.3 | 707 | 11.9 |
| Other | 3,113 | 3.4 | 406 | 6.9 |
| TOTAL | 91,559 | 100.0 | 10,311 | 173.9 |
*Alprazolam; chlordiazepoxide; clonazepam; diazepam; lorazepam
**Not mutually exclusive; exceeds 100%